Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 33, Issue 2, 2010, Pages 175-182

  Trotta, T ^a   Fasanella, A ^b   Scaltrito, D ^b   Gradoni, L ^c   Mitolo, V ^d   Brandonisio, O ^d   Acquafredda, A ^d   Panaro, M A ^d  

^a UNIVERSITY OF FOGGIA   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA PUGLIA E DELLA BASILICATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Adjuvant; Dog; Leishmania; Leishmaniosis; Vaccine

Indexed keywords

ADJUPRIME; IMOVAX BCG; LEISHMANIA INFANTUM PROMASTIGOTE SOLUBLE ANTIGEN PLUS ADJUPRIME; LEISHMANIA INFANTUM PROMASTIGOTE SOLUBLE ANTIGEN PLUS BCG VACCINE; LEISHMANIA INFANTUM PROMASTIGOTE SOLUBLE ANTIGEN PLUS MONOPHOSPHORYL LIPID A PLUS TREHALOSE DICORYNOMYCOLATE PLUS CELL WALL SKELETON; LEISHMANIA VACCINE; N(G) METHYLARGININE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; DOG DISEASE; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; FEMALE; IN VITRO STUDY; LEISHMANIA INFANTUM; LEISHMANIASIS; MACROPHAGE ACTIVATION; MALE; NONHUMAN; PROMASTIGOTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; BCG VACCINE; CELL WALL SKELETON; CORD FACTORS; DOG DISEASES; DOGS; FEMALE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS; LEISHMANIASIS VACCINES; LEUKOCYTES, MONONUCLEAR; LIPID A; MACROPHAGES; MALE; TIME FACTORS;

CANIS FAMILIARIS; LEISHMANIA INFANTUM;

EID: 77649188790     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2009.12.003     Document Type: Article

References (33)

1. Denkers E.Y., Butcher B.A. Sabotage and exploitation in macrophages parasitized by intracellular protozoans. Trends Parasitol 2005, 21(January (1)):35-41.
2. Lisi S., Sisto M., Acquafredda A., Spinelli R., Schiavone M., Mitolo V., et al. Infection with Leishmania infantum inhibits actinomycin D-induced apoptosis of human monocytic cell line U-937. J Eukaryot Microbiol 2005, 52(May-June (3)):211-217.
3. Brandonisio O., Carelli G., Ceci L., Consenti B., Fasanella A., Puccini V. Canine leishmaniasis in the Gargano Promontory (Apulia, South Italy). Eur J Epidemiol 1992, 8:273-276.
4. Gramiccia M., Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 2005, 35(October (11/12)):1169-1180.
5. Paradies P., Capelli G., Cafarchia C., de Caprariis D., Sasanelli M., Otranto D. Incidences of canine leishmaniasis in an endemic area of southern Italy. J Vet Med B Infect Dis Vet Public Health 2006, 53(August (6)):295-298.
6. Oliva G., Scalone A., Foglia Manzillo V., Gramiccia M., Pagano A., Di Muccio T., et al. Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons. J Clin Microbiol 2006, 44(April (4)):1318-1322.
7. Kedzierski L., Zhu Y., Handman E. Leishmania vaccines: progress and problems. Parasitology 2006, 133(Suppl.):S87-S112.
8. Fujiwara R.T., Vale A.M., França da Silva J.C., da Costa R.T., Quetz Jda S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 2005, 36(September-December (5/6)):827-838.
9. Saraiva E.M., de Figueiredo Barbosa A., Santos F.N., Borja-Cabrera G.P., Nico D., Souza L.O., et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 2006, 24(March (13)):2423-2431.
10. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 2007, 25(May (21)):4223-4234.
11. Evans D.A. Methods of cultivating parasites in vitro 1978, 55-58. Academic Press, London. A.E.R. Taylor, J.R. Baker (Eds.).
12. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
13. Pantazis C.G., Kniker W.T. Assessment of blood leukocyte microbial killing by using a new fluorochrome micrassay. J Reticuloendothel Soc 1979, 26:155.
14. Lasri S., Sahibi H., Sadak A., Jaffe C.L., Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 1999, 30:441-449.
15. Cabrera M., Blackwell J.M., Castes M., Trujillo D., Convit J., Shaw M.A. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 2000, 22(February (2)):73-79.
16. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356(November (9241)):1565-1569.
17. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C., et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001, 19(May (25/26)):3485-3492.
18. Molano I., Alonso M.G., Miron C., Redondo E., Requena J.M., Soto M., et al. Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 2003, 92(March (1/2)):1-13.
19. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003, 171:6275-6282.
20. Akramiene D., Kondrotas A., Didziapetriene J., Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 2007, 43(8):597-606.
21. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002, 10(Suppl. 10).
22. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005, 21(May (5)).
23. Chaitra M.G., Nayak R., Shaila M.S. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine 2007, 25:7168-7176.
24. ®) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002, 20:3658-3667.
25. Kropf P., Freudenberg M.A., Modolell M., Price H.P., Herath S., Antoniazi S., et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immunol 2004, 72:1920-1928.
26. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2(April (2)):219-229.
27. Ribi E., Cantrell J., Yakayama K. A new immunomodulator with potential clinical applications: monophosphoryl lipid A, a detoxified endotoxin. Immunol Newslett 1985, 6:33-36.
28. Ribi E., Ulrich J.T., Masihi K.N. Immunopotentiating activities of monophosphoryl lipid A. Progress in leucocyte biology, vol. 6. Immunopharmacology of infectious disease. Vaccine adjuvants and modulators of non-specific resistance 1987, 101-112. Alan R. Liss, Inc., New York. J.A. Majde (Ed.).
29. Jensen M.A., Arnason B.G., White D.M. A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors. Eur J Immunol 2007, 37(April (4)):1139-1148.
30. Bogdan C., Röllinghoff M., Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000, 12(February (1)):64-76.
31. Panaro M.A., Fasanella A., Lisi S., Mitolo V., Andriola A., Brandonisio O. Evaluation of nitric oxide production by Leishmania infantum-infected dog macrophages. Immunopharmacol Immunotoxicol 1998, 20(February (1)):147-158.
32. Sisto M., Brandonisio O., Panaro M.A., Acquafredda A., Leogrande D., Fasanella A., et al. Inducible nitric oxide synthase expression in Leishmania-infected dog macrophages. Comp Immunol Microbiol Infect Dis 2001, 24(October (4)):247-254.
33. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., et al. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet Immunol Immunopathol 2005, 106(July (3/4)):247-257.